Beximco Pharmaceuticals Limited has reported a net profit of Tk 694 crore for the financial year ended in June, alongside the declaration of a substantial cash dividend for its shareholders. The board of directors disclosed the audited results following approval from the Bangladesh Securities and Exchange Commission, bringing long-awaited financial clarity to investors.
For the year 2024–25, the company has approved a total cash dividend of Tk 212 crore, translating into Tk 4.75 per share. The payout structure reflects the company’s existing shareholding pattern, with sponsor-directors holding just over 30 per cent set to receive approximately Tk 64 crore. Foreign investors, who control around 27 per cent of shares, will obtain roughly Tk 58 crore, while institutional investors holding a little over 25 per cent are expected to receive about Tk 54 crore. General retail shareholders will collectively receive close to Tk 36 crore.
The company has fixed 2 August as the record date, meaning only shareholders registered on that date will qualify for the declared dividend. The annual general meeting will follow, after which the dividend distribution process is expected to begin.
The announcement comes after a period of corporate and regulatory uncertainty. Changes in the ownership and governance structure involving prominent sponsor figure Salman F Rahman and his family triggered scrutiny over the board composition. The appointment of independent directors and associated legal and administrative procedures led to repeated delays in board meetings, which in turn slowed the finalisation of financial statements. As a result, investors faced an extended wait for audited disclosures.
The delay also had international implications. The company, which is listed on overseas trading platforms through secondary listings, faced a temporary suspension from the London Stock Exchange’s Alternative Investment Market due to missed reporting deadlines. Extended suspension in such cases carries reputational risks and, if prolonged, can lead to further regulatory consequences, including potential delisting considerations under exchange rules.
Despite the strong earnings announcement, market reaction on the Dhaka Stock Exchange remained subdued. By midday trading on Wednesday, the company’s share price had slipped to around Tk 142. However, trading activity was notably heavy, with Beximco Pharma featuring among the most actively traded stocks of the session, indicating continued investor interest amid volatility.
The pharmaceutical sector remains a key component of Bangladesh’s capital market, with companies like Beximco Pharma playing a significant role in both domestic supply and export earnings. The latest results, while financially solid, also highlight how governance issues and regulatory compliance pressures can directly influence market perception and investor sentiment, even for established industry leaders.